跳至主要内容
临床试验/NCT01709253
NCT01709253已完成不适用

Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma

National Cancer Center, Korea1 个研究点 分布在 1 个国家目标入组 117 人开始时间: 2007年3月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
117
试验地点
1
主要终点
clinical outcomes

研究概览

简要总结

Phase 2 hypofractionation study usion proton beam therapy for prostate adenocarcinoma

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

性别
Male
接受健康志愿者
否

入选标准

  • •Biopsy proven prostate adenocarcinoma Stage: T1-T2cN0M0 ECOG performance status: 0-2 Signed study specific informed consent prior to study entry

排除标准

  • •Postoperative residual or recurrent tumor Evidence of distant metastases Previous irradiation for the tumor in the same location Adjuvant anti-androgenic hormonal therapy High risk group (NCCN guide line)

研究组 & 干预措施

Arm 1

Experimental

27pt/60CGE/20fx/5wks to PGTV(mon, tue, thu, fri; 4/wk)

干预措施: proton beam therapy (Radiation)

Arm 2

Experimental

27pt/54CGE/15fx/5wks to PGTV (mon, wed, fri; 3/wk)

干预措施: proton beam therapy (Radiation)

Arm 3

Experimental

27pt / 47CGE/10fx/5wk to PGTV(tue, thu;2/wk)

干预措施: proton beam therapy (Radiation)

Arm 4

Experimental

27pt/ 35CGE/ 5fx/2.5wk to PGTV(the, thu; 2/wk)

干预措施: proton beam therapy (Radiation)

结局指标

主要结局

clinical outcomes

时间窗: up to 5years from a initial follow-up

To evaluate biochemical failure-free survival (BCFFS)

次要结局

  • acute toxicity(up to 5years from a initial follow-up)
  • late toxicity(up to 5years from a initial follow-up)
  • overall survival(up to 5years from a initial follow-up)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Kwan Ho Cho

M.D.

National Cancer Center, Korea

研究点 (1)

Loading locations...

相似试验